Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa

Pakhchanian, Haig; Raiker, Rahul; DeYoung, Charles; Yang, Sherry

doi:10.1111/ced.15090

Cited by 4 publications

(3 citation statements)

References 5 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…90 However, patients with hidradenitis suppurativa are not at higher risk for any COVID-19 vaccine-related adverse outcomes. 91,92 Urticarial rashes are the second most common cutaneous reaction following COVID-19 vaccination reported, following local injection site reactions, such as "Covid-arm". 93 Globally, 98 cases of urticarious eruptions following COVID-19 vaccination have been collected in our review, 77,78,83,[94][95][96][97][98][99][100][101][102][103][104][105][106][107] also during treatment with omalizumab.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

Section: Resultsmentioning

confidence: 99%

“… 90 However, patients with hidradenitis suppurativa are not at higher risk for any COVID-19 vaccine‐related adverse outcomes. 91 , 92 …”

Section: Resultsmentioning

confidence: 99%

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

show abstract

“…39 To sum up, the role of telemedicine in patients affected by HS seems to be limited since several concerns remain such as patient emotional distress, patient comfort and privacy, difficulties to show intimate areas, inability for clinicians to palpate lesions. [40][41][42][43][44] Thus, new strategies and new studies are required.…”

Section: Dovepressmentioning

confidence: 99%

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review

Ruggiero¹,

Fabbrocini²,

Villani³

et al. 2022

CCID

View full text Add to dashboard Cite

Teledermatology represented one of the most important and useful tools during the COVID-19 pandemic era. Indeed, due to the severe restriction, and to reduce the spread of the infection, different measures were applied among different countries and hospitals to ensure a continuity of care for patients. In this scenario, teledermatology played a central role, especially in the management of patients suffering from chronic inflammatory skin diseases. The aim of this narrative review is to describe the role of teledermatology during the COVID-19 pandemic to analyze main strengths and limitations of this tool, as well as to provide future perspectives in clinical applications.

show abstract

Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa’

Marasca

Battista

Fabbrocini

et al. 2022

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

241 of 562 patients (42.9%) were on anti-TNF-a, 179 (31.9%) on anti-IL-17, 114 (20.3%) on anti-IL-12/23, and 28 (5%) were on anti-IL-23 agents. All patients had been vaccinated against influenza and COVID-19, depending on the availability of the latter during the particular time period. Biological therapy was not interrupted in any case of SARS-CoV-2 infection either by the dermatologist or at the patient's request.Of the 562 affected patients, 432 patients (76.9%) experienced an exacerbation of psoriasis during COVID-19 infection defined as an increase in PASI by at least 4 points. Remarkable sustained efficacy with a change in PASI of ≤ 4 was observed in patients receiving IL-17 inhibitors, with 112 patients (62.6%) maintaining their absolute PASI, which outperformed the other agents (P < 0.05). The second most durable biologic in terms of efficacy was anti-TNF-a (18 of 241), but this also had a high rate of relapsed patients (92.5%). In addition, 67 patients treated with anti-IL-17 agents experienced a relapse. All patients treated with anti-IL-12/23 or anti-IL-23 demonstrated an increase in PASI of ≥ 4 (Table 1), but this regression in psoriasis was transient and as brief as 10 days (mean AE SD 30 AE 20 days). No modification in treatment regimen nor agent switch was required due to psoriasis exacerbation.Our study suggests that biologic treatments for psoriasis, particularly anti-IL-17 agents, sustain their beneficial results in the long run even during COVID-19 infection. Given that SARS-CoV-2 seems to initiate an IL-17-enriched response, this might explain why different active principles could lead, even temporarily, to different degrees of effectiveness. 2-4 However, larger long-term studies are needed to draw definite conclusions.

show abstract

Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa

Cited by 4 publications

References 5 publications

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review

Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa’

Contact Info

Product

Resources

About